16-30 of 101
Barton Lynn Blackorby, MD
Katharine Talcott, MD
Hong-Uyen Hua, MD
Maria H. Berrocal, MD
Avni P. Finn, MD, MBA
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Eye on Ocular HealthDistinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Ashkan Abbey, MD
Retinal Vein Occlusion: The Case for Prompt Treatment
Eye on Ocular HealthRetinal Vein Occlusion: The Case for Prompt Treatment
Ashkan Abbey, MD
Identifying Central and Branch Retinal Vein Occlusion
Eye on Ocular HealthIdentifying Central and Branch Retinal Vein Occlusion
Jessica Randolph, MD
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Eye on Ocular HealthTime to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
- advertisement
Outcomes for PDR Patients LTFU for at Least 1 Year
New Retina RadioOutcomes for PDR Patients LTFU for at Least 1 Year
Kyle Davis Kovacs, MD
Matt Starr, MD
Nita Valikodath, MD, MS
Examining Therapeutic Timing in RVO-Related Macular Edema
Eye on Ocular HealthExamining Therapeutic Timing in RVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
OphthalmologyReal-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Maria H. Berrocal, MD
Lejla Vajzovic, MD, FASRS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Eye on Ocular HealthHow Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
Alexis Warren, MD
Jesse Sengillo, MD
Sruthi Arepalli, MD
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
OphthalmologySuprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Maria H. Berrocal, MD
Danny Mammo, MD
- advertisement
Overcoming Barriers in Dry Eye Disease Care: Current and Emerging Options
Eye on Ocular HealthOvercoming Barriers in Dry Eye Disease Care: Current and Emerging Options
Houman Hemmati, MD, PhD
Cleaner Air, Clearer Vision: Uncovering Air Pollution’s Role in Childhood Myopia
Eye on Ocular HealthCleaner Air, Clearer Vision: Uncovering Air Pollution’s Role in Childhood Myopia
Risk of RVO in Type 2 Diabetes: GLP-1 Receptor Agonists Versus DPP-4 Inhibitors
Eye on Ocular HealthRisk of RVO in Type 2 Diabetes: GLP-1 Receptor Agonists Versus DPP-4 Inhibitors
Marlene Mimi Maeusli, PhD.
